Atypical Dermatitis Herpetiform and Scalp Psoriasis in Ulcerative Colitis Patient Treated With Adalimumab
Adalimumab is a blocker of tumor necrosis factor (TNF)-alpha with established efficacy in the treatment of ulcerative colitis. However, literature indicated that adalimumab can, occasionally, induce paradoxical psoriasis reactions and, very rarely, dermatitis herpetiformis. We present a unique case...
Gespeichert in:
| Veröffentlicht in: | Curēus (Palo Alto, CA) CA), 2023-02, Vol.15 (2), p.e35317 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | e35317 |
| container_title | Curēus (Palo Alto, CA) |
| container_volume | 15 |
| creator | Alshehri, Hamza Alshehri, Afnan Bin Abbas, Abrar |
| description | Adalimumab is a blocker of tumor necrosis factor (TNF)-alpha with established efficacy in the treatment of ulcerative colitis. However, literature indicated that adalimumab can, occasionally, induce paradoxical psoriasis reactions and, very rarely, dermatitis herpetiformis. We present a unique case of a 26-year-old female patient who developed a combination of dermatitis herpetiformis and scalp psoriasis paradoxically as a result of adalimumab treatment for ulcerative colitis. To the best of our knowledge, this is the first case of such a combination within the context of adalimumab therapy. The etiopathological underpinning of such a reaction remains elusive but is speculated to be complex and involves the interaction of several immunological and dermatological mechanisms. Adalimumab therapy is associated with a genuine risk for the development of paradoxical psoriasis and dermatitis herpetiformis. We, through this case report, added to the evidence confirming such an association. Clinicians should follow these potential adverse effects and make every effort to warn patients of their likelihood. |
| doi_str_mv | 10.7759/cureus.35317 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9947429</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2780651029</sourcerecordid><originalsourceid>FETCH-LOGICAL-c266t-f4e726c0fa68bd8b8b9330e8176a2eecb8a8f2b60e1f4c132c83ab4161d440353</originalsourceid><addsrcrecordid>eNpVkUtLAzEUhYMoKurOtQTc2ppk0iSzEUp9gmBBi8uQydyxKfMyyQj-e2NbRVe54Xz35JCD0CklYykn-aUdPAxhnE0yKnfQIaNCjRRVfPfPfIBOQlgRQiiRjEiyjw4yobgQnB4iN42fvbOmxtfgGxNddAHfg-8huqrzDTZtiZ-T3uN56LwzIemuxYvagk_4B-BZV6-35ukKbcQvHkyEEr-6uMTT0tSuGRpTHKO9ytQBTrbnEVrc3rzM7kePT3cPs-njyDIh4qjiIJmwpDJCFaUqVJFnGQFFpTAMwBbKqIoVggCtuKUZsyozBaeClpyT9BFH6Grj2w9FA6VNkbypde9dY_yn7ozT_5XWLfVb96HznEvO8mRwvjXw3fsAIepVN_g2ZdZMKiImlKypiw1lfReCh-r3BUr0dzd6041ed5Pws7-pfuGfJrIvsy-Npg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2780651029</pqid></control><display><type>article</type><title>Atypical Dermatitis Herpetiform and Scalp Psoriasis in Ulcerative Colitis Patient Treated With Adalimumab</title><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Alshehri, Hamza ; Alshehri, Afnan ; Bin Abbas, Abrar</creator><creatorcontrib>Alshehri, Hamza ; Alshehri, Afnan ; Bin Abbas, Abrar</creatorcontrib><description>Adalimumab is a blocker of tumor necrosis factor (TNF)-alpha with established efficacy in the treatment of ulcerative colitis. However, literature indicated that adalimumab can, occasionally, induce paradoxical psoriasis reactions and, very rarely, dermatitis herpetiformis. We present a unique case of a 26-year-old female patient who developed a combination of dermatitis herpetiformis and scalp psoriasis paradoxically as a result of adalimumab treatment for ulcerative colitis. To the best of our knowledge, this is the first case of such a combination within the context of adalimumab therapy. The etiopathological underpinning of such a reaction remains elusive but is speculated to be complex and involves the interaction of several immunological and dermatological mechanisms. Adalimumab therapy is associated with a genuine risk for the development of paradoxical psoriasis and dermatitis herpetiformis. We, through this case report, added to the evidence confirming such an association. Clinicians should follow these potential adverse effects and make every effort to warn patients of their likelihood.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.35317</identifier><identifier>PMID: 36846641</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Allergy/Immunology ; Biopsy ; Case reports ; Dermatitis ; Dermatology ; Disease ; Inflammatory bowel disease ; Monoclonal antibodies ; Patients ; Psoriasis ; Rheumatoid arthritis ; Tumor necrosis factor-TNF</subject><ispartof>Curēus (Palo Alto, CA), 2023-02, Vol.15 (2), p.e35317</ispartof><rights>Copyright © 2023, Alshehri et al.</rights><rights>Copyright © 2023, Alshehri et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2023, Alshehri et al. 2023 Alshehri et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c266t-f4e726c0fa68bd8b8b9330e8176a2eecb8a8f2b60e1f4c132c83ab4161d440353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947429/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947429/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36846641$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alshehri, Hamza</creatorcontrib><creatorcontrib>Alshehri, Afnan</creatorcontrib><creatorcontrib>Bin Abbas, Abrar</creatorcontrib><title>Atypical Dermatitis Herpetiform and Scalp Psoriasis in Ulcerative Colitis Patient Treated With Adalimumab</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Adalimumab is a blocker of tumor necrosis factor (TNF)-alpha with established efficacy in the treatment of ulcerative colitis. However, literature indicated that adalimumab can, occasionally, induce paradoxical psoriasis reactions and, very rarely, dermatitis herpetiformis. We present a unique case of a 26-year-old female patient who developed a combination of dermatitis herpetiformis and scalp psoriasis paradoxically as a result of adalimumab treatment for ulcerative colitis. To the best of our knowledge, this is the first case of such a combination within the context of adalimumab therapy. The etiopathological underpinning of such a reaction remains elusive but is speculated to be complex and involves the interaction of several immunological and dermatological mechanisms. Adalimumab therapy is associated with a genuine risk for the development of paradoxical psoriasis and dermatitis herpetiformis. We, through this case report, added to the evidence confirming such an association. Clinicians should follow these potential adverse effects and make every effort to warn patients of their likelihood.</description><subject>Allergy/Immunology</subject><subject>Biopsy</subject><subject>Case reports</subject><subject>Dermatitis</subject><subject>Dermatology</subject><subject>Disease</subject><subject>Inflammatory bowel disease</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>Psoriasis</subject><subject>Rheumatoid arthritis</subject><subject>Tumor necrosis factor-TNF</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpVkUtLAzEUhYMoKurOtQTc2ppk0iSzEUp9gmBBi8uQydyxKfMyyQj-e2NbRVe54Xz35JCD0CklYykn-aUdPAxhnE0yKnfQIaNCjRRVfPfPfIBOQlgRQiiRjEiyjw4yobgQnB4iN42fvbOmxtfgGxNddAHfg-8huqrzDTZtiZ-T3uN56LwzIemuxYvagk_4B-BZV6-35ukKbcQvHkyEEr-6uMTT0tSuGRpTHKO9ytQBTrbnEVrc3rzM7kePT3cPs-njyDIh4qjiIJmwpDJCFaUqVJFnGQFFpTAMwBbKqIoVggCtuKUZsyozBaeClpyT9BFH6Grj2w9FA6VNkbypde9dY_yn7ozT_5XWLfVb96HznEvO8mRwvjXw3fsAIepVN_g2ZdZMKiImlKypiw1lfReCh-r3BUr0dzd6041ed5Pws7-pfuGfJrIvsy-Npg</recordid><startdate>20230222</startdate><enddate>20230222</enddate><creator>Alshehri, Hamza</creator><creator>Alshehri, Afnan</creator><creator>Bin Abbas, Abrar</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20230222</creationdate><title>Atypical Dermatitis Herpetiform and Scalp Psoriasis in Ulcerative Colitis Patient Treated With Adalimumab</title><author>Alshehri, Hamza ; Alshehri, Afnan ; Bin Abbas, Abrar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c266t-f4e726c0fa68bd8b8b9330e8176a2eecb8a8f2b60e1f4c132c83ab4161d440353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Allergy/Immunology</topic><topic>Biopsy</topic><topic>Case reports</topic><topic>Dermatitis</topic><topic>Dermatology</topic><topic>Disease</topic><topic>Inflammatory bowel disease</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>Psoriasis</topic><topic>Rheumatoid arthritis</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alshehri, Hamza</creatorcontrib><creatorcontrib>Alshehri, Afnan</creatorcontrib><creatorcontrib>Bin Abbas, Abrar</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alshehri, Hamza</au><au>Alshehri, Afnan</au><au>Bin Abbas, Abrar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atypical Dermatitis Herpetiform and Scalp Psoriasis in Ulcerative Colitis Patient Treated With Adalimumab</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2023-02-22</date><risdate>2023</risdate><volume>15</volume><issue>2</issue><spage>e35317</spage><pages>e35317-</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Adalimumab is a blocker of tumor necrosis factor (TNF)-alpha with established efficacy in the treatment of ulcerative colitis. However, literature indicated that adalimumab can, occasionally, induce paradoxical psoriasis reactions and, very rarely, dermatitis herpetiformis. We present a unique case of a 26-year-old female patient who developed a combination of dermatitis herpetiformis and scalp psoriasis paradoxically as a result of adalimumab treatment for ulcerative colitis. To the best of our knowledge, this is the first case of such a combination within the context of adalimumab therapy. The etiopathological underpinning of such a reaction remains elusive but is speculated to be complex and involves the interaction of several immunological and dermatological mechanisms. Adalimumab therapy is associated with a genuine risk for the development of paradoxical psoriasis and dermatitis herpetiformis. We, through this case report, added to the evidence confirming such an association. Clinicians should follow these potential adverse effects and make every effort to warn patients of their likelihood.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>36846641</pmid><doi>10.7759/cureus.35317</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2168-8184 |
| ispartof | Curēus (Palo Alto, CA), 2023-02, Vol.15 (2), p.e35317 |
| issn | 2168-8184 2168-8184 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9947429 |
| source | PubMed Central; PubMed Central Open Access |
| subjects | Allergy/Immunology Biopsy Case reports Dermatitis Dermatology Disease Inflammatory bowel disease Monoclonal antibodies Patients Psoriasis Rheumatoid arthritis Tumor necrosis factor-TNF |
| title | Atypical Dermatitis Herpetiform and Scalp Psoriasis in Ulcerative Colitis Patient Treated With Adalimumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T14%3A26%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atypical%20Dermatitis%20Herpetiform%20and%20Scalp%20Psoriasis%20in%20Ulcerative%20Colitis%20Patient%20Treated%20With%20Adalimumab&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Alshehri,%20Hamza&rft.date=2023-02-22&rft.volume=15&rft.issue=2&rft.spage=e35317&rft.pages=e35317-&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.35317&rft_dat=%3Cproquest_pubme%3E2780651029%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2780651029&rft_id=info:pmid/36846641&rfr_iscdi=true |